TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03944902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: Dose Escalation
Description: The first 3 participants will be enrolled on a fixed dose of Niraparib and CB-839, 600mg. Participants will be evaluated for DLT's, if there are none, they will be enrolled in the next cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Dose Escalation
Description: If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Dose Escalation
Description: If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
Study: NCT05095714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liver ultrasound and fast-MRI
Description: Half-yearly liver ultrasound and fast-MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liver ultrasound
Description: Half-yearly liver ultrasound
Study: NCT05615480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled hypotension guided by cerebral oxygen saturation monitoring
Description: In this group, intraoperative monitoring of cerebral oxygen saturation will be used. When the cerebral oxygen saturation decreased by 20% \~ 25% compared with the baseline for 300 seconds without improvement, or the cerebral oxygen saturation decreased by 25% \~ 30% compared with the baseline for 180 seconds without improvement, intervention would be carried out. When the cerebral oxygen saturation decreased by 30% compared with the baseline, immediate intervention would be carried out. The intervention measures were intravenous administration of deoxyepinephrine 50 \~ 100 μg or ephedrine 5 \~ 10mg, which can be administered multiple times until the cerebral oxygen saturation reaches more than 80% of the baseline.
Study: NCT04931199

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The standard of care procedures for children with clinically elevated anxiety, depression, and PTSD is traditional CBT from their mental health provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT+App
Description: Participants receive CBT as usual enhanced with a simple, HIPAA compliant, web-based application to help mental health providers implement homework during CBT with children with elevated PTSD, anxiety, and/or depression, and their caregivers. The three major components of the app help providers to (1) Practice interactive, digitized CBT exercises with patients in-session; (2) Remind patients to practice CBT exercises for homework, and (3) Review homework during the next session.
Study: NCT04777097

Intervention type: OTHER
Intervention: Blood sample
Description: Two blood sample will be drawn. On the day of operation and the first postoperative day.

Intervention type: OTHER
Intervention: Blood sample
Description: Two blood sample will be drawn. On the day of operation and the first postoperative day.
Study: NCT05317221

Intervention type: OTHER
Intervention: Not an extra intervention, tissue taken in routine practice will be used.
Description: No extra intervention: using tumour tissue taken during surgery in standard of care.
Study: NCT04063345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Description: Performing intravascular ultrasound before or/and after percutaneous intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Performing percutaneous intervention without intravascular ultrasound guidance
Study: NCT06217497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot massage
Description: Patients in the experimental group were subjected to a foot massage with baby oil for 10 minutes during HD treatment three times a week for four weeks, 12 times in total. At the end of the second and fourth weeks after the foot massage, the second and third readings were recorded by repeating the PFS and PSQI
Study: NCT05971017

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Lettuce without any biostimulation was assigned to each participant belonging to the control group which ate 100gr every day for 15 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biostimulated group
Description: Intervention biostimulated group 100gr of biostimulated lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 15 days
Study: NCT06645925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Step Protocol
Description: FGG will be done simultaneous with implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two Steps Protocol
Description: Conventional FGG protocol, prior to implant placement
Study: NCT05317299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 different type of exercise
Description: Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 different type of exercise
Description: Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 different type of exercise
Description: Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training
Study: NCT04935762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-103, CST-107, matching placebo
Description: CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-103, CST-107, matching placebo
Description: CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
Study: NCT05923411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as first Tablet Formulation
Description: A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as second Tablet Formulation
Description: A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as first Tablet Formulation
Description: A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as second Tablet Formulation
Description: A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as a Tablet Formulation
Description: A single dose of PF-07220060 as a tablet formulation administered under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration
Description: A 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration
Description: A 2-treatment fixed sequence of a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal followed by a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of PF-07220060 as third tablet formulation
Description: A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them
Study: NCT06525662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation using an endotracheal tube with a 30 degree straight to cuff shape
Description: Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation using an endotracheal tube with an arcuate cuff shape
Description: Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
Study: NCT05730153

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: advanced PRF
Description: advanced PRF+ surgery

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: advanced PRF
Description: advanced PRF+ surgery
Study: NCT05615610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spine TENS
Description: The participants in Group A will receive TENS (Burst mode, 9 pulses per burst, pulse frequency = 160 Hz, burst frequency = 2 Hz) with upper limb exercises. The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Two 7.5 × 12.6 cm electrodes will be attached between C6 and T5 level on each side of spinal column and with 2 cm from the spine. Intensity of TENS will be individually selected by the participants according to tolerance levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tVNS
Description: The participants in Group B will receive tVNS (pulse frequency = 25Hz, pulse duration = 0.3 ms) on the cymba conchae of left outer ear with upper limb exercises.The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Intensity of tVNS will be individually selected by the participants according to tolerance levels. Previous studies showed that it was effective to improve the upper limb motor function in people with stroke and cognitive function in people with mild cognitive function.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The participants in Group C will receive placebo tVNS with upper limb exercises, where the stimulation will be delivered by placebo-TENS device with disconnected electrical circuit.
Study: NCT05680831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.070 ppm ozone concentration
Description: The concentration of ozone a subject will randomly receive on a visit for 6.6 hours in a controlled atmospheric chamber while performing moderate intermittent exercise.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clean air (0.0 ppm ozone)
Description: Same subject will randomly receive clean air on another visit separated by at least one week for 6.6 hours in the same controlled atmospheric chamber while performing moderate intermittent exercise.
Study: NCT05274542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity with blood flow restriction
Description: Participants in high intensity with blood flow restriction group (n=12) will be given high-intensity resistance exercise training that restricts blood flow. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. A blood pressure cuff will be used to restrict blood flow. By applying the cuff to the proximal of the muscle, the blood flow will be restricted with a pressure of 150 mmHg and the muscle will be exercised in this way. After the exercise, the cuff will be removed and evaluations will be made after 2 minutes of rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high intensity without blood flow restriction group
Description: Participants in high intensity without blood flow restriction group (n=12) will be given high-intensity resistance exercise training. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. After the exercise, after 2 minutes of rest, evaluations will be made.
Study: NCT05545345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tympanostomy tube placement
Description: An incision will be made in the the tympanic membrane, through which a ventilation tube will be inserted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tympanostomy tube placement
Description: An incision will be made in the the tympanic membrane, through which a ventilation tube will be inserted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adenoidectomy
Description: The adenoid is resected transorally under a 70° endoscope with microdebrider or coblator until torus tubarius and choanae are completely revealed.
Study: NCT05093426

Intervention type: OTHER
Intervention: Stage 2 Digital sleep diary app
Description: Participants in Stage 2 will be asked to download a digital sleep diary app and complete a sleep log every day for 21 days.
Study: NCT06479252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sit-to-Stand Test (STS)
Description: The 30-s and 1-min STS tests are reliable, valid, and responsive tests for measuring functional exercise capacity in patients with lung disease. For the STS tests that are centre-based or supervised remotely, investigators will collect the total number of repetitions on the 30-s and 1-min STS tests, as well as the number and duration of rests within and between tests.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-to-Stand Test (STS)
Description: The 30-s and 1-min STS tests are reliable, valid, and responsive tests for measuring functional exercise capacity in patients with lung disease. For the STS tests that are centre-based or supervised remotely, investigators will collect the total number of repetitions on the 30-s and 1-min STS tests, as well as the number and duration of rests within and between tests.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-to-Stand Test (STS)
Description: The 30-s and 1-min STS tests are reliable, valid, and responsive tests for measuring functional exercise capacity in patients with lung disease. For the STS tests that are centre-based or supervised remotely, investigators will collect the total number of repetitions on the 30-s and 1-min STS tests, as well as the number and duration of rests within and between tests.
Study: NCT04713813

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise program via hippotherapy mechanical stimulator
Description: Patients were planned to complete hippotherapy exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic home exercise program
Description: Patients were planned to complete home exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
Study: NCT06135779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Lust for Life
Description: A Lust For Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting List Control
Description: Control group placed on a 12-week waiting list for the A Lust for Life School programme.
Study: NCT03125187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium heparin UQ Intravenous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium heparin UQ Intravenous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium heparin FK Intravenous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
Study: NCT04770142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIRA catheter
Description: treat hypertrophic obstructive cardiomyopathy
Study: NCT03125187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium heparin FK Intravenous drug administration
Description: The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
Study: NCT04875026

Intervention type: DRUG
Group type: OTHER
Intervention: 5-fluorouracil 4% (Tolak)
Description: Application of Tolak once daily in the evening for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil 4% (Tolak)
Description: Application of Tolak once daily in the evening for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexeryl
Description: Application of Dexeryl once daily in the morning for 8 weeks
Study: NCT06253741

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PARAVERTEBRAL BLOCK
Description: Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RHOMBOID INTERCOSTAL AND SUBSERRATUS PLANE BLOCK
Description: Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
Study: NCT05451615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janus Kinase Inhibitor
Description: One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
Study: NCT05311566

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Concurrent chemoradiotherapy
Description: Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy. After completing 6\~8weeks of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until disease progression or unacceptable toxicity.
Study: NCT05412225

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre-neoadjuvant radiotherapy (NART) biopsy
Description: Participants will undergo pre-NART core biopsy guided by post-NAC MRI to the area of residual enhancement or to the previously biopsied cancer if no residual enhancement remains

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: After biopsy, participants will undergo neoadjuvant radiotherapy/NART

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral total mastectomy with axillary lymph node dissection
Description: At 2-6 weeks after completion of NART, participants will undergo unilateral MRM (total mastectomy with axillary lymph node dissection), with resection of all involved breast skin. Skin-sparing mastectomy will not be permitted. All patients will also undergo simultaneous unilateral autologous-based breast reconstruction with DIEP, ms-TRAM, or latissimus dorsi flap.
Study: NCT06505551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCG142
Description: Autologous SCG142 cells infused on Day 0 after completion of lymphedepletion chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: for 3 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: for 3 consecutive days